TY - JOUR
KW - Adult
KW - Buprenorphine/administration & dosage
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Naloxone/administration & dosage
KW - office visits
KW - Opioid-Related Disorders/drug therapy/epidemiology
KW - Patient Satisfaction
KW - Primary Health Care/methods
KW - Treatment Outcome
AU - D. T. Barry
AU - B. A. Moore
AU - M. V. Pantalon
AU - M. C. Chawarski
AU - L. E. Sullivan
AU - P. G. O'Connor
AU - R. S. Schottenfeld
AU - D. A. Fiellin
A1 - 
AB - BACKGROUND: Factors associated with satisfaction among patients receiving primary care-based buprenorphine/naloxone are unknown. OBJECTIVE: To identify factors related to patient satisfaction in patients receiving primary care-based buprenorphine/naloxone that varied in counseling intensity (20 vs 45 minutes) and office visit frequency (weekly vs thrice weekly). DESIGN AND PARTICIPANTS: One hundred and forty-two opioid-dependent subjects. MEASUREMENTS: Demographics, drug treatment history, and substance use status at baseline and during treatment were collected. The primary outcome was patient satisfaction at 12 weeks. RESULTS: Patients' mean overall satisfaction score was 4.4 (out of 5). Patients were most satisfied with the medication and ancillary services and indicated strong willingness to refer a substance-abusing friend for the same treatment. Patients were least satisfied with their interactions with other opioid-dependent patients, referrals to Narcotics Anonymous, and the inconvenience of the treatment location. Female gender (beta = .17, P = .04) and non-White ethnicity/race (beta = .17, P = .04) independently predicted patient satisfaction. Patients who received briefer counseling and buprenorphine/naloxone dispensed weekly had greater satisfaction than those whose medication was dispensed thrice weekly (mean difference 4.9, 95% confidence interval 0.08 to 9.80, P = .03). CONCLUSIONS: Patients are satisfied with primary care office-based buprenorphine/naloxone. Providers should consider the identified barriers to patient satisfaction.
BT - Journal of general internal medicine
C5 - Opioids & Substance Use
CP - 2
CY - United States
DO - 10.1007/s11606-006-0050-y
IS - 2
JF - Journal of general internal medicine
N2 - BACKGROUND: Factors associated with satisfaction among patients receiving primary care-based buprenorphine/naloxone are unknown. OBJECTIVE: To identify factors related to patient satisfaction in patients receiving primary care-based buprenorphine/naloxone that varied in counseling intensity (20 vs 45 minutes) and office visit frequency (weekly vs thrice weekly). DESIGN AND PARTICIPANTS: One hundred and forty-two opioid-dependent subjects. MEASUREMENTS: Demographics, drug treatment history, and substance use status at baseline and during treatment were collected. The primary outcome was patient satisfaction at 12 weeks. RESULTS: Patients' mean overall satisfaction score was 4.4 (out of 5). Patients were most satisfied with the medication and ancillary services and indicated strong willingness to refer a substance-abusing friend for the same treatment. Patients were least satisfied with their interactions with other opioid-dependent patients, referrals to Narcotics Anonymous, and the inconvenience of the treatment location. Female gender (beta = .17, P = .04) and non-White ethnicity/race (beta = .17, P = .04) independently predicted patient satisfaction. Patients who received briefer counseling and buprenorphine/naloxone dispensed weekly had greater satisfaction than those whose medication was dispensed thrice weekly (mean difference 4.9, 95% confidence interval 0.08 to 9.80, P = .03). CONCLUSIONS: Patients are satisfied with primary care office-based buprenorphine/naloxone. Providers should consider the identified barriers to patient satisfaction.
PP - United States
PY - 2007
SN - 1525-1497; 0884-8734
SP - 242
EP - 245
EP - 
T1 - Patient satisfaction with primary care office-based buprenorphine/naloxone treatment
T2 - Journal of general internal medicine
TI - Patient satisfaction with primary care office-based buprenorphine/naloxone treatment
U1 - Opioids & Substance Use
U2 - 17356993
U3 - 10.1007/s11606-006-0050-y
VL - 22
VO - 1525-1497; 0884-8734
Y1 - 2007
ER -